RevolKa Ltd., a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform called aiProtein®, has raised 210 million JPY (US$1.4M) in Series A extension funding. This funding will advance RevolKa’s drug discovery programs for rare diseases (https://www.revolka.com/news/english/collab-en/a65) and support collaborative partnering efforts. This financing round was co-led by existing investors, D3 LLC and TOHOKU University Venture Partners Co., Ltd. with participation from DEEPCORE Inc.
RevolKa’s core technology, aiProtein® is a robust AI-driven protein engineering technology that creates exceptionally high-performance proteins. This technology platform has already produced many successful outcomes in collaboration with partner companies.
RevolKa’s proprietary aiProtein® platform is an AI-assisted protein engineering platform. Proteins are linear polymers composed of amino acids and their derivatives, folding into a tertiary structure through internal complex atomic interactions to exhibit biological functions. The relationship between protein sequence, structure, and function remains poorly understood, limiting rational design of protein. AlphaFold developed by Google DeepMind that was awarded the Nobel prize in Chemistry in 2024 has provided an AI-driven solution to the protein sequence-to-structure relationship. aiProtein®, in turn, addresses the protein sequence-to-function relationship.
Also Read: Fujifilm Finds Cancer Targeting Potential in New Peptides
RevolKa’s AI engine is trained on sequence-to-function relationship data, enabling the efficient generation of sequences of proteins with desired functions. Furthermore, aiProtein® can simultaneously engineer multiple properties, offering a powerful and cost-effective solution for creating novel and highly functional proteins suitable for pharmaceutical and industrial applications.
SOURCE: BusinessWire
